SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Minimal Clip Art Collage. Pop Vector Design Composition with bright bold geometric shapes, halftone objects for ad, animation etc
Approvals
J&J Steps Into Crowded Myasthenia Gravis Market With FDA Nod
With Imaavy, J&J will go toe-to-toe with fellow Big Pharma AstraZeneca, which owns Soliris and Ultomiris.
May 1, 2025
 · 
2 min read
 · 
Tristan Manalac
complex business management or organization, distraction and complicated business process
Government
FDA Misses Another Deadline Amid Staff Exodus, Structural Disruptions
The FDA has lost several senior employees in recent weeks, including some who have been at the agency for more than two decades.
May 1, 2025
 · 
2 min read
 · 
Tristan Manalac
An illustration showing a cartoon man wearing a suit and holding a sledge hammer, standing on an abstract fractured American flag
Editorial
RFK Jr. Is Driving a Wedge Into Already Polarized Vaccine Conversations
When it comes to vaccination, the COVID-19 pandemic divided American society. President Donald Trump and his new Health and Human Services secretary are bringing down the hammer. What happens when there is no middle ground?
May 1, 2025
 · 
7 min read
 · 
Jef Akst
Paying double wages or giving double money, greed and lust, double work for double wages, one person splitting into two and claiming both
Deals
Novartis Strikes on M&A, Leading a Line of Big Pharmas With Cash to Spend
Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome sign for the biopharma ecosystem, which has been battered by macro headwinds such as tariffs and the possibility of new drug pricing pressures.
April 30, 2025
 · 
5 min read
 · 
Annalee Armstrong
Illustration showing knowledge sharing between two people
Leadership
Leadership Lab: 9 Tips for Fully Benefiting From an Executive Coach
Learn how to extract the full value from executive coaching, starting with being open and honest with your coach.
April 30, 2025
 · 
4 min read
 · 
Michael Pietrack
command failed. Business team walk in a line following faulty orders vector
Layoffs
Entrada Cuts 20% of Workforce, Targeting Research Employees
Entrada is paring back its research staff even as it gears up to hire employees to support a planned clinical trial for a Duchenne muscular dystrophy candidate.
April 30, 2025
 · 
1 min read
 · 
Angela Gabriel
Chicago, Illinois, USA on Lake Michigan at dawn.
Cancer
AACR 2025 Tracker: Merck, GSK, Roche and More Present Key Data
The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates and assets, including Merck’s Keytruda and GSK’s Jemperli.
April 30, 2025
 · 
8 min read
 · 
BioSpace Editorial Staff
Mergers & acquisitions
Novartis Drops up to $1.7B to Bolster Oligo Pipeline With Regulus Buy
At the heart of the acquisition is Regulus’ farabursen, an miRNA-targeting oligonucleotide in early-stage development for rare autosomal dominant polycystic kidney disease.
April 30, 2025
 · 
2 min read
 · 
Tristan Manalac
Poznan, Poland - 5 October 2024: GSK -Glaxosmithkline headquarters office building in Poznan.
Earnings
GSK Optimistic About M&A Prospects Despite Trump Tariff Threats
GSK’s dealmaking will be “cautious and disciplined” under the current trade war, but the pharma will focus on looking for “opportunities created” amid these tensions, according to CEO Emma Walmsley. The company also reported a 4% earnings bump for the quarter.
April 30, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS